CHD4 regulates platinum sensitivity through MDR1 expression in ovarian cancer: A potential role of CHD4 inhibition as a combination therapy with platinum agents

被引:19
作者
Oyama, Yoshiko [1 ]
Shigeta, Shogo [1 ]
Tokunaga, Hideki [1 ]
Tsuji, Keita [1 ]
Ishibashi, Masumi [1 ]
Shibuya, Yusuke [1 ]
Shimada, Muneaki [1 ]
Yasuda, Jun [2 ]
Yaegashi, Nobuo [1 ]
机构
[1] Tohoku Univ, Dept Obstet & Gynecol, Grad Sch Med, Sendai, Miyagi, Japan
[2] Miyagi Canc Ctr, Div Mol & Cellular Oncol, Res Inst, Natori, Miyagi, Japan
来源
PLOS ONE | 2021年 / 16卷 / 06期
关键词
HOMOLOGOUS RECOMBINATION; MOLECULAR-MECHANISMS; CLINICAL-TRIAL; DNA-REPAIR; CISPLATIN; RESISTANCE; CARCINOMA; COMPLEX; P21; SUPPRESSION;
D O I
10.1371/journal.pone.0251079
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Platinum sensitivity is an important prognostic factor in patients with ovarian cancer. Chromodomain-helicase-DNA-binding protein 4 (CHD4) is a core member of the nucleosome remodeling and deacetylase complex, which functions as a chromatin remodeler. Emerging evidence indicates that CHD4 could be a potential therapeutic target for cancer therapy. The purpose of this study was to clarify the role of CHD4 in ovarian cancer and investigate its therapeutic potential focusing on platinum sensitivity. In an analysis of the Cancer Genome Atlas ovarian cancer dataset, CHD4 gene amplification was associated with worse overall survival. CHD4 mRNA expression was significantly higher in platinum-resistant samples in a subsequent clinical sample analysis, suggesting that CHD4 overexpression conferred platinum resistance to ovarian cancer cells, resulting in poor patient survival. In concordance with these findings, CHD4 knockdown enhanced the induction of apoptosis mediated by cisplatin in ovarian cancer cells TOV21G and increased cisplatin sensitivity in multiple ovarian cancer cells derived from different subtypes. However, CHD4 knockdown did not affect the expression of RAD51 or p21, the known targets of CHD4 in other cancer types that can modulate platinum sensitivity. Knockdown and overexpression assays revealed that CHD4 positively regulated the expression of multi-drug transporter MDR1 and its coding protein p-glycoprotein. In addition, a first-in-class CHD4/SMARCA5 inhibitor ED2-AD101 showed synergistic interactions with cisplatin. Our findings suggest that CHD4 mediates platinum sensitivity by modulating MDR1 expression in ovarian cancer. Further, CHD4 suppression has a potential to be a novel therapeutic strategy in combination with platinum agents.
引用
收藏
页数:18
相关论文
共 63 条
  • [21] Molecular mechanisms of cisplatin resistance
    Galluzzi, L.
    Senovilla, L.
    Vitale, I.
    Michels, J.
    Martins, I.
    Kepp, O.
    Castedo, M.
    Kroemer, G.
    [J]. ONCOGENE, 2012, 31 (15) : 1869 - 1883
  • [22] p21: A Two-Faced Genome Guardian
    Georgakilas, Alexandros G.
    Martin, Olga A.
    Bonner, William M.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2017, 23 (04) : 310 - 319
  • [23] Cisplatin: The first metal based anticancer drug
    Ghosh, Sumit
    [J]. BIOORGANIC CHEMISTRY, 2019, 88
  • [24] The Chromatin Remodeling Complex Chd4/NuRD Controls Striated Muscle Identity and Metabolic Homeostasis
    Gomez-del Arco, Pablo
    Perdiguero, Eusebio
    Sofia Yunes-Leites, Paula
    Acin-Perez, Rebeca
    Zeini, Miriam
    Garcia-Gomez, Antonio
    Sreenivasan, Krishnamoorthy
    Jimenez-Alcazar, Miguel
    Segales, Jessica
    Lopez-Maderuelo, Dolores
    Ornes, Beatriz
    Jesus Jimenez-Borreguero, Luis
    D'Amato, Gaetano
    Enshell-Seijffers, David
    Morgan, Bruce
    Georgopoulos, Katia
    Islam, Abul B. M. M. K.
    Braun, Thomas
    Luis de la Pompa, Jose
    Kim, Johnny
    Enriquez, Jose A.
    Ballestar, Esteban
    Munoz-Canoves, Pura
    Miguel Redondo, Juan
    [J]. CELL METABOLISM, 2016, 23 (05) : 881 - 892
  • [25] Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
    Gourley, Charlie
    Balmana, Judith
    Ledermann, Jonathan A.
    Serra, Violeta
    Dent, Rebecca
    Loibl, Sibylle
    Pujade-Lauraine, Eric
    Boulton, Simon J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2257 - +
  • [26] Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4
    Guillemette, Shawna
    Serra, Ryan W.
    Peng, Min
    Hayes, Janelle A.
    Konstantinopoulos, Panagiotis A.
    Green, Michael R.
    Cantor, Sharon B.
    [J]. GENES & DEVELOPMENT, 2015, 29 (05) : 489 - 494
  • [27] Carcinoma of the ovary
    Heintz, APM
    Odicino, F
    Maisonneuve, P
    Beller, U
    Benedet, JL
    Creasman, WT
    Ngan, HYS
    Pecorelli, S
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2003, 83 : 135 - 166
  • [28] The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia
    Heshmati, Yaser
    Turkoz, Gozde
    Harisankar, Aditya
    Kharazi, Shabnam
    Bostrom, Johan
    Dolatabadi, Esmat Kamali
    Krstic, Aleksandra
    Chang, David
    Mansson, Robert
    Altun, Mikael
    Qian, Hong
    Walfridsson, Julian
    [J]. HAEMATOLOGICA, 2018, 103 (07) : 1169 - 1181
  • [29] CHD3 and CHD4 form distinct NuRD complexes with different yet overlapping functionality
    Hoffmeister, Helen
    Fuchs, Andreas
    Erdel, Fabian
    Pinz, Sophia
    Groebner-Ferreira, Regina
    Bruckmann, Astrid
    Deutzmann, Rainer
    Schwartz, Uwe
    Maldonado, Rodrigo
    Huber, Claudia
    Dendorfer, Anne-Sarah
    Rippe, Karsten
    Laengst, Gernot
    [J]. NUCLEIC ACIDS RESEARCH, 2017, 45 (18) : 10534 - 10554
  • [30] The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer
    Hou, Ming-Feng
    Luo, Chi-Wen
    Chang, Tsung-Ming
    Hung, Wen-Chun
    Chen, Tzu-Yi
    Tsai, Ya-Li
    Chai, Chee-Yin
    Pan, Mei-Ren
    [J]. EXPERIMENTAL CELL RESEARCH, 2017, 359 (02) : 458 - 465